Very Late Recurrence of Hepatocellular Carcinoma After Orthotopic Liver Transplantation: Presentation and Management No abstract available

Staged Biliary Reconstruction After Orthotopic Liver Transplantation: A Practical Surgical Strategy for High-Acuity Adult Recipients Background. Biliary complications (BC) following orthotopic liver transplantation (OLT) is strongly associated with inferior patient outcomes and increased healthcare cost. BC in high-acuity patients can be lethal. While the utility of staged biliary reconstruction after liver transplantation (SBRALT) has been reported in adult and pediatric OLT, biliary outcome data are scarce. We sought to evaluate the clinical utility and outcomes of SBRALT in high-acuity transplant recipients. Methods. We conducted an analysis from our prospective database of 149 adult OLT between January 1, 2012, and September 30, 2017. Mean follow-up was 26 months. Variables were compared for Group I: one-stage OLT with biliary reconstruction (N = 58) versus Group II: SBRALT (N = 91). Results. Compared with Group I, patients in Group II had higher acuity of illness: median model for end-stage liver disease scores (19 vs 35 P = 0.002), requirement for pretransplant intensive care unit (29.3% vs 54.9%, P = 0.022), pretransplant renal replacement therapy (15.5% vs 48.4%), estimated blood loss (2000 vs 4750 mL, P < 0.001), and intraoperative packed red blood cells transfusion (4 vs 10 units, P < 0.001). For Group II, biliary reconstruction was performed between 1 and 6 days after OLT. Hepaticojejunostomy was performed in 8.6% (Group I) and 26.4% (Group II), P = 0.010. For Groups I and II, BC rates (8.6% vs 7.7%, P = 0.955) and 1-year graft failure-free survival rates (89.7% vs 88.2%, P = 0.845) were comparable. Conclusions. Graft failure-free survival and biliary outcomes of SBRALT in high-acuity recipients are excellent and comparable to one-stage OLT for low-risk patients. SBRALT is a practical surgical strategy in complex OLT. Received 3 June 2019. Revision received 23 June 2019. Accepted 24 June 2019. Published online 8 August, 2019. T.P., M.A.Z., J.K., P.A.P., C.M.E., M.W., M.A.S., D.M., and J.C.H. participated in research design, participated in the performance of research, and contributed new reagents or analytic tools. T.P., M.A.Z., J.K., D.M., and J.C.H. participated in the writing of the paper. T.P., M.A.Z., D.M., and J.C.H. participated in data analysis. The authors declare no conflicts of interest. This work was supported in part by The Kevin T. Cottrell Memorial Fund for Organ Transplantation Research. Correspondence: Johnny C. Hong, MD, Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Transplant Center, 9200 W. Wisconsin Avenue, CFAC 2nd Floor, Suite H2200, Milwaukee, WI 53226. (jhong@mcw.edu). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. © 2019 The Authors. Published by Wolters Kluwer Health, Inc.

Circulating B Cells With Memory and Antibody-Secreting Phenotypes Are Detectable in Pediatric Kidney Transplant Recipients Before the Development of Antibody-Mediated Rejection Background. Development of anti–human leukocyte antigen donor-specific antibodies (DSAs) is associated with antibody-mediated rejection (AMR) and reduced allograft survival in kidney transplant recipients. Whether changes in circulating lymphocytes anticipate DSA or AMR development is unclear. Methods. We used time-of-flight mass cytometry to analyze prospectively collected peripheral blood mononuclear cells (PBMC) from pediatric kidney transplant recipients who developed DSA (DSA-positive recipients [DSAPOS], n = 10). PBMC were obtained at 2 months posttransplant, 3 months before DSA development, and at DSA detection. PBMC collected at the same time points posttransplant from recipients who did not develop DSA (DSA-negative recipients [DSANEG], n = 11) were used as controls. Results. DSAPOS and DSANEG recipients had similar baseline characteristics and comparable frequencies of total B and T cells. Within DSAPOS recipients, there was no difference in DSA levels (mean fluorescence intensity [MFI]: 13 687 ± 4159 vs 11 375 ± 1894 in DSAPOSAMR-positive recipients (AMRPOS) vs DSAPOSAMR-negative recipients (AMRNEG), respectively; P = 0.630), C1q binding (5 DSAPOSAMRPOS [100%] vs 4 DSAPOSAMRNEG [80%]; P = 1.000), or C3d binding (3 DSAPOSAMRPOS [60%] vs 1 DSAPOSAMRNEG [20%]; P = 0.520) between patients who developed AMR and those who did not. However, DSAPOS patients who developed AMR (n = 5; 18.0 ± 3.6 mo post-DSA detection) had increased B cells with antibody-secreting (IgD−CD27+CD38+; P = 0.002) and memory (IgD-CD27+CD38−; P = 0.003) phenotypes compared with DSANEG and DSAPOSAMRNEG recipients at DSA detection. Conclusions. Despite the small sample size, our comprehensive phenotypic analyses show that circulating B cells with memory and antibody-secreting phenotypes are present at DSA onset, >1 year before biopsy-proven AMR in pediatric kidney transplant recipients. Received 10 May 2019. Accepted 16 May 2019. Published online 8 August, 2019. C.F. and M.F. are co-first authors. L.P. and P. Cravedi are co-senior authors. This work was supported by the GOFARR Foundation and the Schenkman Family. F.C. received internal funding from the Icahn School of Medicine and NIDDK-T32 DK007757-18S1; this study was also supported by a grant from Fondazione Compagnia San Paolo to M. Cioni, and a grant from IRCCS Policlinico San Matteo, Progetti Ricerca Corrente to P. Comoli. The authors declare no conflicts of interest. C.F. and M.F. participated in the performance of the research, data analysis, and writing of the paper. G.F., M. Cioni, P. Comoli, A.N., M. Cardillo, C.C., L.G., A.P., and S.D.S. participated in the performance of the research. L.P. participated in study design, writing of the paper, and data analysis. P. Cravedi had the original idea and participated in research design, writing of the paper, and data analysis. Previous Presentation: This study was presented in part as oral communication at the American Society of Nephrology Renal Week; October 24th 2018 (SA-OR088); San Diego, CA and at the American Transplant Congress; 2019 (19-A-2963); Boston. Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (www.transplantationdirect.com). Correspondence: Paolo Cravedi, MD, PhD, Icahn School of Medicine at Mount Sinai, 1 Levy Pl, 10029 New York, NY. (paolo.cravedi@mssm.edu). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. © 2019 The Authors. Published by Wolters Kluwer Health, Inc.

Renal Outcomes of Liver Transplantation Recipients Receiving Standard Immunosuppression and Early Renal Sparing Immunosuppression: A Retrospective Single Center Study Background. New-onset stage 4–5 chronic kidney disease (CKD) after liver transplantation (LT) is associated with high morbidity, mortality, and economic burden. In 2010, we instituted an early renal sparing immunosuppression (RSI) protocol for LT recipients with severe renal dysfunction (pre-LT dialysis/estimated glomerular filtration rate (eGFR)<30mL/min/1.73 m2 or post-LT acute kidney injury) consisting of 2 doses of basiliximab for induction and delaying tacrolimus to post-LT day 4–7. We examined the effect of early RSI on post-LT renal outcomes. Methods. Data on all adults who had LT between January 1, 2010, and December 12, 2014 were collected. We calculated the renal risk index (RRI) score for each LT recipient (https://rri.med.umich.edu). Primary outcome was new-onset post-LT stage 4–5 CKD. Results. Of 214 LT recipients, 121 (57%) received early RSI and 93 (43%) received standard immunosuppression. Cumulative incidence of new-onset stage 4–5 CKD was higher in early RSI compared with standard immunosuppression (P = 0.03). Female sex and RRI score were the significant risk factors for development of post-LT stage CKD in the entire study cohort as well as the LT recipients with RRI ≥ sixth decile (high-risk group). Conclusions. Delaying tacrolimus initiation combined with basiliximab induction did not have a durable effect on long-term renal outcomes in high-risk LT recipients. Further studies are needed to identify the effective strategies to preserve renal function by targeting patients at high risk for CKD progression. Received 3 May 2019. Revision received 24 May 2019. Accepted 3 June 2019. Published online 08 August, 2019. P.S., C.J.S., and J.M.P. participated in research design, performance of research, data analysis, writing, editing, and revision. Y.S., J.N., J.E., and J.S. participated in the performance of research, data collection, and writing of the manuscript. S.T. participated in performance of research, data analysis, writing, editing, and revision. The authors declare no funding or conflicts of interest. Previous Presentation: This study was presented in part at the annual AASLD meeting; November 9–13, 2018; San Francisco, CA. Correspondence: Pratima Sharma, MD, MS, Division of Gastroenterology and Hepatology, Michigan Medicine, University of Michigan, 3912 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109. (pratimas@med.umich.edu). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. © 2019 The Authors. Published by Wolters Kluwer Health, Inc.